| 4.3149 0.365 (9.24%) | 03-12 13:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.38 |
1-year : | 6.28 |
| Resists | First : | 4.61 |
Second : | 5.38 |
| Pivot price | 4.01 |
|||
| Supports | First : | 3.89 |
Second : | 3.45 |
| MAs | MA(5) : | 4.01 |
MA(20) : | 3.95 |
| MA(100) : | 3.48 |
MA(250) : | 3.11 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.6 |
D(3) : | 52.9 |
| RSI | RSI(14): 66.6 |
|||
| 52-week | High : | 4.61 | Low : | 1.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GRCE ] has closed above the upper band by 5.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 54.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.02 - 4.04 | 4.04 - 4.06 |
| Low: | 3.9 - 3.92 | 3.92 - 3.94 |
| Close: | 3.92 - 3.95 | 3.95 - 3.98 |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Tue, 10 Mar 2026
Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update - MarketBeat
Sat, 28 Feb 2026
Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update - MarketBeat
Wed, 25 Feb 2026
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Thu, 19 Feb 2026
Companies Like Grace Therapeutics (NASDAQ:GRCE) Are In A Position To Invest In Growth - Sahm
Thu, 12 Feb 2026
Grace Therapeutics (GRCE) Advances Towards FDA Review with Promi - GuruFocus
Thu, 12 Feb 2026
Grace Therapeutics Q3 2026 Financial Results and Business Update - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 27 (%) |
| Held by Institutions | 28 (%) |
| Shares Short | 65 (K) |
| Shares Short P.Month | 43 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.9 % |
| Return on Equity (ttm) | -10.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -14.09 |
| PEG Ratio | 0 |
| Price to Book value | 1.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|